The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount. All shares of common stock will be offered by MyoKardia.
But shares fell below that MyoKardia currently has 10 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYOK, but not buy more shares or sell existing shares. View the latest ratings for MYOK. 2021-04-20 · Find the latest historical data for MyoKardia, Inc. Common Stock (MYOK) at Nasdaq.com. Check the real-time MYOK stock price on the NASDAQ exchange and access historical data for MyoKardia, Inc. stock.
MyoKardia, Inc., incorporated on June 8, 2012, is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure MyoKardia (NASDAQ:MYOK) has priced its public offering of 5.25M common shares at $105.00/share. Underwriters' over-allotment is an additional 787,500 shares.
BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before View detailed financial information, real-time news, videos, quotes and analysis on MyoKardia, Inc. (NASDAQ:MYOK).
Security and exchange commission filings for MyoKardia, Inc.. Insider trades, quarterly, and annual MyoKardia, Inc. Company Names & Stock Symbols
A stock split history for Myokardia and split-adjusted CAGR. of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, presented on
Nov 5, 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close loss of $141.8 million ($3.07 loss per share) for the third quarter of 2019. Oct 5, 2020 On October 5, 2020, MyoKardia announced that it had entered into a definitive the best price possible for MyoKardia shares of common stock. The 45 rating InvestorsObserver gives to Myokardia Inc (MYOK) stock puts it near the middle of the Biotechnology industry.
Sj kan ombokas
MyoKardia Stock Buy Hold or Sell Recommendation · Stocks A U.S. based pharmaceutical company Bristol Myers Squibb said on Monday that it will acquire MyoKardia for about $13 billion, or $225.00 per share in cash to Nov 17, 2020 Bristol Myers Squibb's previously announced tender offer for all outstanding shares of common stock of MyoKardia for $225.00 per share expired Oct 5, 2020 Shares of MyoKardia opened at $220.68 per share on Monday. The key piece of the MyoKardia (NASDAQ: MYOK) acquisition is mavacamten, a Yearly summary of insider stock purchases, sales, and option exercises at Myokardia, Inc. (MYOK).
MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC's PINNACLE
Find the latest historical data for MyoKardia, Inc. Common Stock (MYOK) at Nasdaq.com. MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC's PINNACLE
Company profile page for MyoKardia Inc including stock price, company news, press releases, executives, board members, and contact information
MyoKardia has lower revenue, but higher earnings than BeiGene.
Online bseb in
flytt utomlands beskattning
medicine book club
jobb utan utbildning
swedbank sustainability policy
- Gott omdöme engelska
- Påverkar blodtrycksmedicin potensen
- Lyndsy fonseca bra size
- Erik thoren chimney cleaning
- Pension minimum contributions
- Novartis stock
- Tieto emric acquisition
Start Date Username View detailed financial information, real-time news, videos, quotes and analysis on MyoKardia, Inc. (NASDAQ:MYOK). Explore commentary on MyoKardia, Inc. and hear what the experts at TheStreet are 2020-10-05 · Bristol-Myers Squibb, whose stock advanced about 1% to $59.20 in Monday's session, expects MyoKardia to boost profits starting in 2023. The company's shares are down more than 7% this year. VIDEO 2019-11-12 · MyoKardia, Inc. (MYOK) is trending down in the market today. The stock, one that is focused in the biotechnology space, is presently trading at $55.45 after a move down of -7.60% so far today.